CoChat

Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non–Small Cell Lung Cancer

Open access
Gettinger, Scott N., Wurtz, Anna, Goldberg, Sarah B., Rimm, David, Schalper, Kurt, Kaech, Susan, Kavathas, Paula, Chiang, Anne, Lilenbaum, Rogerio, Zelterman, Daniel, Politi, Katerina, Herbst, Roy S. · 2018 · Journal of Thoracic Oncology
Cited by 135

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Introduction: With expanding indications for programmed death 1 (PD‐1) axis inhibitors in non–small cell lung cancer (NSCLC), acquired resistance (AR) to these therapies is increasingly being encountered. We sought to characterize clinical patterns of AR to PD‐1 axis inhibitors in patients with advanced NSCLC, and evaluate subsequent outcome and management strategies for such patients. Methods: Patients with NSCLC who developed AR to PD‐1 axis inhibitor therapy initiated between December 2009 and February 2016 at one institution were identified and examined by clinical and radiographic features. AR was defined as progressive disease after initial response by either Response Evaluation Criteria in Solid Tumors v1.1 or immune‐related response criteria. Results: Twenty‐six patients with AR to PD‐1 axis inhibitor therapy were identified and evaluated. Median time to AR was 313 days; the 2‐year survival rate from AR was 70% (95% confidence interval: 0.53–0.92). Twenty patients (77%) experienced AR in lymph nodes (LNs), including 11 patients with LN‐only progression. Twenty‐three (88%) patients had recurrence limited to one (54%) or two (35%) sites of disease. Fourteen patients (54%) continued PD‐1 axis inhibitor therapy beyond progression. Three patients were re‐challenged with the same PD‐1 axis inhibitor after holiday from and progression off therapy, 2 again responded. Fifteen patients (58%) received local therapy to site(s) of AR, 11 continued respective PD‐1 axis inhibitor after local therapy. The 2‐year survival rate from AR among these 15 patients was 92% (95% confidence interval: 0.77–1). Conclusions: Acquired resistance to PD‐1 axis inhibitors is often limited to one or two sites when local therapy and continuation of PD‐1 axis inhibitor therapy can result in prolonged benefit. LN metastases appear to be particularly susceptible sites to AR. When progression of disease following response occurs after holiday from PD‐1 axis inhibitor, re‐challenge can again lead to tumor regression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2018.03.008

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

Metadata

Authors
Gettinger, S. N., Wurtz, A., Goldberg, S. B., Rimm, D., Schalper, K., Kaech, S., Kavathas, P., Chiang, A., Lilenbaum, R., Zelterman, D., Politi, K., & Herbst, R. S.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2018-06
Volume
13
Issue
6
Pages
831-839
ISSN
1556-0864 (ISSN-L)
OpenAlex
W2791856118
Cited by
135
References
9
FWCI
5.06
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.